Correspondence 0001683168-23-008505 from Z Squared Inc. (COEP)
Z Squared Inc.
Date: Nov. 28, 2023 · CIK: 0001759186 · Accession: 0001683168-23-008505
AI Filing Summary & Sentiment
File numbers found in text: 333-275558
Letter
Coeptis Therapeutics Holdings, Inc.
105 Bradford Rd, Suite 420
Wexford, Pennsylvania 15090
November 28, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Lauren S. Hammil
Re: Coeptis Therapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed on November 15, 2023
File No. 333-275558
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the above-referenced Registration Statement such that it may become effective tomorrow, November 29, 2023, at 5:00 p.m. Eastern Time.
The Registrant hereby acknowledges that:
(i)should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii)the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii)the Registrant may not assert the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Meister Seelig & Fein PLLC, by calling Denis Dufresne at (212) 655-3548 (also can be reached at dad@msf-law.com).
Thank you for your assistance in this matter.
Very truly yours,
COEPTIS
THERAPEUTICS HOLDINGS, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Coeptis Therapeutics
Holdings, Inc.
105 Bradford Rd, Suite 420
Wexford, Pennsylvania 15090
November 28, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Lauren S. Hammil
Re: Coeptis Therapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed on November 15, 2023
File No. 333-275558
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations
under the Securities Act of 1933, as amended, the undersigned, Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Registrant”),
hereby requests acceleration of the effective date of the above-referenced Registration Statement such that it may become effective tomorrow,
November 29, 2023, at 5:00 p.m. Eastern Time.
The Registrant hereby acknowledges that:
(i)should
the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the
Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii)the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does
not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement;
and
(iii)the
Registrant may not assert the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration
Statement effective as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the
United States.
Once the Registration
Statement has been declared effective, please orally confirm that event with our counsel, Meister Seelig & Fein PLLC,
by calling Denis Dufresne at (212) 655-3548 (also can be reached at dad@msf-law.com).
Thank you for your assistance in this matter.
Very truly yours,
COEPTIS
THERAPEUTICS HOLDINGS, Inc.
By: /s/ David Mehalick
Name: David Mehalick
Title: Chief Executive Officer
cc: Denis Dufresne, Esq., Meister Seelig & Fein
PLLC